Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study.
Gridelli, C de Marinis, F Thomas, M Prabhash, K El Kouri, C Bustin, F Pujol, J John, W San Antonio, B
Gridelli, C
de Marinis, F
Thomas, M
Prabhash, K
El Kouri, C
Bustin, F
Pujol, J
John, W
San Antonio, B
Citations
Altmetric:
Abstract
The PARAMOUNT Phase III trial showed that maintenance pemetrexed after pemetrexed plus cisplatin induction was well tolerated and effective for patients with advanced nonsquamous non-small-cell lung cancer. Approximately 17% of patients receiving maintenance therapy in this study were 70 years of age or older. Here we report efficacy and safety results from the PARAMOUNT study for elderly (≥70 years) and non-elderly (<70 years) patients.
Description
Date
2014-07
Publisher
Collections
Keywords
Type
Article
Citation
Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study. 2014, 9 (7):991-7 J Thorac Oncol